OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mauro on the Risks of Disease Progression in Myelofibrosis

August 31st 2021

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Dr. Ward on the Benefits of Delaying Salvage Therapy in Prostate Cancer

August 31st 2021

Matthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.

Dr. Martin on Key Advances in Multiple Myeloma

August 31st 2021

Thomas G. Martin, MD, discusses recent key advances in multiple myeloma.

Dr. Lyou on Key Takeaways from the ENZAMET Trial in Metastatic Prostate Cancer

August 31st 2021

Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.

Dr. Wenham on the Potential for Immunotherapy in Ovarian Cancer

August 31st 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses the potential for immunotherapy in ovarian cancer.

Dr. Dorff on Biomarkers of Response to PARP Inhibitors in Prostate Cancer

August 30th 2021

Tanya B. Dorff, MD, discusses biomarkers of response to PARP inhibitors under investigation in prostate cancer.

Dr. Lyou on the Efficacy of ADT Plus Docetaxel in High-Volume mHSPC

August 30th 2021

Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Dr. Zhang on the State of Risk Stratification in mCRPC

August 30th 2021

Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.

Dr. Torres-Roca on Optimizing Radiation Therapy With GARD-Based Dosing in Oncology

August 30th 2021

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology

August 30th 2021

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Patil on Key Developments With Targeted Therapy in Lung Cancer

August 26th 2021

Pradnya D. Patil, MD, FACP, discusses recent developments with targeted therapies in lung cancer.

Dr. Abida on Future Research Directions in mCRPC

August 26th 2021

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Chu on Ongoing Efforts to Address Disparities in Lung Cancer

August 26th 2021

Edward Chu, MD, MMS, discusses ongoing efforts to address disparities in lung cancer at Montefiore and Albert Einstein College of Medicine.

Dr. Garg on the Emergence of Antiandrogen Agents in nmCRPC

August 25th 2021

Natasha Garg, DO, discusses the emergence of antiandrogen agents in the nonmetastatic castration-resistant prostate cancer treatment paradigm.

Dr. Goldman on Key Takeaways From the CASPIAN Trial in Frontline ES-SCLC

August 25th 2021

Jonathan W. Goldman, MD, discusses key takeaways from the phase 3 CASPIAN trial in patients with extensive-stage small cell lung cancer.

Dr. Dietrich on Navigating the NSCLC Treatment Landscape

August 25th 2021

Martin Dietrich, MD, PhD, shares how he navigates the non–small cell lung cancer (NSCLC) treatment landscape.

Dr. Eskander on the Utility of Lymphadenectomy in Endometrial Cancer

August 25th 2021

Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.

Dr. Burnham on Correlations Between Race and HER2 Positivity in Prostate Cancer

August 24th 2021

Leanne Burnham, PhD, discusses the correlation between HER2 positivity and race in patients with prostate cancer.

Dr. Pecot on Addressing Mechanisms of Resistance With New Targeted Therapies in NSCLC

August 24th 2021

Chad V. Pecot, MD, discusses addressing mechanisms of resistance with new targeted therapies in non–small cell lung cancer.

Dr. Agarwal on the Efficacy of Intensified ADT in mHSPC

August 24th 2021

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.